IMWG Myeloma Experts debate the latest trends in treatment June 10, 2015 Vienna Austria Drs. Brian Durie, Joseph Mikhael, Ola Landgren, and Paul Richardson discusses the following topics: Diagnostic Criteria Revised ISS staging and personalized medicine MRD testing/response criteria The challenge of double refractory disease Drug costs and access: 2015 and beyond Visit our website at: http://www.myeloma.org Find us online: Facebook: http://facebook.com/myeloma Google+: http://gplus.to/imfmyeloma IMF on twitter: @IMFMyeloma (http://twitter.com/imfmyeloma) Dr. Durie on twitter: @BrianDurieMD (http://twitter.com/brianduriemd)
Author: admin
IMWG Myeloma Experts debate the latest trends in treatment June 10, 2015 Vienna Austria Drs. Brian Durie, Joseph Mikhael, Ola Landgren, and Paul Richardson discusses the following topics: Diagnostic Criteria Revised ISS staging and personalized medicine MRD testing/response criteria The challenge of double refractory disease Drug costs and access: 2015 and beyond Visit our website at: http://www.myeloma.org Find us online: Facebook: http://facebook.com/myeloma Google+: http://gplus.to/imfmyeloma IMF on twitter: @IMFMyeloma (http://twitter.com/imfmyeloma) Dr. Durie on twitter: @BrianDurieMD (http://twitter.com/brianduriemd) Support the IMF! http://bit.ly/WskQHC
IMWG Myeloma Experts debate the latest trends in treatment June 10, 2015 Vienna Austria Visit our website at: http://www.myeloma.org Find us online: Facebook: http://facebook.com/myeloma Google+: http://gplus.to/imfmyeloma IMF on twitter: @IMFMyeloma (http://twitter.com/imfmyeloma) Dr. Durie on twitter: @BrianDurieMD (http://twitter.com/brianduriemd) Support the IMF! http://bit.ly/WskQHC
In this week’s video, Dr. Brian Durie discusses Selinexor, a novel, orally administered drug that is currently ongoing clinical trials. Bottom Line: Selinexor is a promising new type of drug that can make a difference for myeloma patients. Visit our website at: http://www.myeloma.org Find us online: Facebook: http://facebook.com/myeloma Google+: http://gplus.to/imfmyeloma IMF on twitter: @IMFMyeloma (http://twitter.com/imfmyeloma) Dr. Durie on twitter: @BrianDurieMD (http://twitter.com/brianduriemd)
In this weeks video, Dr. Brian Durie gives an update on the IMFs signature research project, Black Swan Research Initative. Bottom Line: The BSRI team is expanding worldwide and exciting progress is being made.
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, discusses the interim analysis of the randomised, double-blind, placebo-controlled, phase 3 HELIOS trial, which evaluated ibrutinib, a Bruton’s tyrosine kinase inhibitor, combined with bendamustine and rituximab (BR) versus vs BR plus placebo in patients with previously treated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ, discusses the results of ENDEAVOR, a randomised, open-label, phase 3 trial comparing carfilzomib plus dexamethasone versus bortezomib plus dexamethasone in patients with relapsed multiple myeloma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, provides an update on IMAAGEN, a multicentre, open-label, single-arm, phase 2 trial evaluating the effect of abiraterone acetate plus prednisone on prostate specific antigen and radiographic disease progression in patients with non-metastatic castration-resistant prostate cancer without radiographic evidence of metastatic disease. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, Omaha, NE, discusses ASCO’s Conquer Cancer Foundation, which was set up to improve cancer care by funding research, sharing knowledge worldwide and supporting access to treatments. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, discusses the results of an analysis that evaluated the effect of a once-daily 420 mg dose of ibrutinib, a Bruton’s tyrosine kinase inhibitor, on progression-free survival in patients with previously treated chronic lymphocytic leukaemia from the phase 3 RESONATE trial. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute, London, UK, explains that the development of immunotherapies for a variety of cancer types and specific cancer proteins is a very active area of research at Sarah Cannon Research Institute. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Georgina Long, BSc, PhD, MBBS, FRACP, of the University of Sydney, Sydney, Australia, discusses current research into treatments that target mechanistic events in the development of melanoma, and how the results of such research can be applied in the clinic. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Learn more about current trends in myeloma treatment and research with this update from three major medical meetings held in June 2015. Dr. Brian G.M. Durie will explain what’s new and exciting from the American Society of Clinical Oncology (ASCO), the European Hematology Association (EHA), and the International Myeloma Working Group Summit (IMWG). Go to www.2015ASCOrecap.myeloma.org to download the slides used in the teleconference.
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hyman Muss, MD, of the University of North Carolina, Chapel Hill, NC, provides an update on the CALGB/CTSU/Alliance 49907 trial, which compared capecitabine with standard chemotherapy in patients with breast cancer who were at least 65 years old. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 20th Congress of the European Hematology Association (EHA), Marek Trn?ný, MD, PhD, of Charles University, Prague, Czech Republic, discusses new data that support earlier treatment of patients with mantle cell lymphoma (MCL), including the results of an investigation of a bortezomib-based regimen as frontline therapy for patients with newly diagnosed MCL. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Eleni Efstathiou, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, TX, reviews the progress of biomarker discovery and validation for informing clinical decision-making in the management of patients with prostate cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 14th St. Gallen International Breast Cancer Conference 2015, Masakazu Toi, MD, PhD, of Kyoto University, Japan, explains that there are still only limited data available regarding the genomic profile of breast tumours in Japanese patients. Information gained from pathological assessment and multigene assays, such as the Oncotype DX® Breast Cancer Assay and MammaPrint, needs to be compiled to further understand breast cancer as a disease and to determine how molecular profiling can be applied in the clinic. In Japan, multigene assays for breast cancer are not currently part of the healthcare system. However, Dr Toi believes that these…
Dr. Boccia talks about the importance of controlling costs in the current environment and how the bioT3 testing approach can help compared to other options. For more information, visit: http://www.cancertypeid.com
Dr Stephen C. Malamud and Dr Susan K. Boolbol discuss payer adoption of the Breast Cancer IndexSM (BCI) to ensure patient access and cost reimbursement. For more information, visit: http://www.breastcancerindex.com http://www.answersbeyond5.com http://www.twitter.com/answersbyond5 http://www.facebook.com/answersbeyond5
At the 20th Congress of the European Hematology Association (EHA), Andrew Davies, BSc (Hons), BM (Hons), MRCP, PhD, of the University of Southampton, Southampton, UK, discusses clinical trials of new treatments for Hodgkin lymphoma (HL). Topics of interest include bendamustine-containing regimen (BeGEV) as induction chemotherapy prior to autologous stem cell transplantation for patients with relapsed or refractory HL and the phase 1 trial of doxorubicin, vinblastine, dacarbazine, and lenalidomide (AVD-Rev) for elderly patients with HL. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 20th Congress of the European Hematology Association (EHA), Sagar Lonial, MD, of the Winship Cancer Institute, Emory University, Atlanta, GA, discusses promising monoclonal antibodies in clinical development for the treatment of patients with multiple myeloma. Prof Lonial focuses on the basic and clinical aspects of several novel monoclonal antibodies, including daratumumab, which targets CD38, and elotuzumab, which targets signalling lymphocytic activation molecule-F7 (SLAMF7). European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Kidney Test
Dr. Geo Espinosa of NYU Langone Medical Center talks about the holistic approach in patient care in Integrative Urology which combines traditional therapies and complementary medicine for maximum patient benefit.
Dr Stephen C. Malamud and Dr Susan K. Boolbol discuss the importance of using a clinically validated test such as the Breast Cancer Index (BCI) and its impact on patient confidence in their treatment plan. For more information, visit: http://www.breastcancerindex.com http://www.answersbeyond5.com http://www.twitter.com/answersbyond5 http://www.facebook.com/answersbeyond5
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sumanta K. Pal, MD, of City of Hope Comprehensive Cancer Center, Duarte, CA, discusses the results of the randomised controlled phase 2 Borealis-1 trial, which evaluated the efficacy and safety of gemcitabine and cisplatin with and without apatorsen, a novel antisense oligonucleotide that inhibits heat shock protein 27 (Hsp27) production, in patients with metastatic bladder cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Ruben A. Mesa, MD, of Mayo Clinic, Arizona, TX, discusses the ongoing PERSIST-2 trial, which is a multicentre, randomised phase 3 trial comparing the efficacy and safety of pacritinib versus best available therapy in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Thomas Powles. MBBS, MRCP, MD, of Barts Cancer Institute, Queen Mary University of London, London, UK, provides an overview of promising novel immunotherapeutic strategies that are currently under investigation for the treatment of patients with kidney cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute, London, UK, discusses the results of the phase 3 COMBI-d trial, which compared the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Karim Fizazi, MD, PhD, of the Institut Gustave Roussy, Villejuif, France, discusses the ongoing phase 3 ARAMIS trial, which is evaluating the efficacy and safety of the novel androgen receptor inhibitor, ODM-201, in men with high-risk non-metastatic castration-resistant prostate cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, discusses the results of a phase 1b trial that evaluated the safety and efficacy of the PI3K? inhibitor, idelalisib, in combination with chemoimmunotherapy for patients with relapsed or refractory chronic lymphocytic leukaemia (CLL). Investigated combinations include idelalisib in combination with rituximab; ofatumumab; bendamustine and rituximab; fludarabine; and chlorambucil. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Lisa A. Carey, MD, of the University of North Carolina, Chapel Hill, NC, discusses the results of the double-blind, phase 3 PALOMA-3 trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Liquid biopsies (also called serum testing) is a practice already approved in Europe for EGFR lung cancer patients. Drawing blood to test for acquired resistance is easier and quicker than needle biopsies. How long until it is standard practice in the US?
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jeremy S. Abramson, MD, of the Massachusetts General Hospital Cancer Center, Boston, MA, discusses a multicentre phase 2 study, which is evaluating brentuximab vedotin plus adriamycin, vinblastine and dacarbazine (AVD) for patients with non-bulky limited-stage Hodgkin lymphoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ, discusses the results of the phase 3 ELOQUENT-2 trial of lenalidomide and dexamethasone with or without elotuzumab in patients with relapsed or refractory multiple myeloma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, elected ASCO President for the 20152016 term, Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, Omaha, NE, summarises the concept of precision medicine in cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, discusses the immune responses and clinical outcomes in STAND, a randomised phase 2 study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in men with biochemically recurrent prostate cancer after local therapy failure. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Lodovico Balducci, MD, of Moffitt Cancer Center, Tampa, FL, explains the current landscape and unmet clinical needs in geriatric oncology. Older patients have highly variable physiologic ages, so there is an increasing emphasis on individualising treatment to optimise clinical outcomes. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Paolo A. Ascierto, MD, of Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, Naples, Italy, discusses the median progression-free survival (PFS) evaluation and correlative biomarker analysis from coBRIM, a phase 3 study of cobimetinib plus vemurafenib in patients with advanced BRAF-mutated melanoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hyman Muss, MD, of the University of North Carolina, Chapel Hill, NC, discusses the increasing focus on physiological factors in preference to chronological age in determining optimal treatment decisions in older patients with breast cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Thomas Powles. MBBS, MRCP, MD, of Barts Cancer Institute, Queen Mary University of London, London, UK, discusses the results of a phase 2/3 trial, which evaluated if maintenance therapy with lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, after first-line chemotherapy is associated with clinical benefit in patients with HER1/2-positive metastatic transitional cell carcinoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
The results of the Oncotype DX® Breast Cancer Assay are reported as a Recurrence Score® a number ranging from 0 to 100. This number indicates the likelihood that a woman’s breast cancer will spread to another area of her body within 10 years of her initial diagnosis. The lower the score is, the lower the chances are that the woman’s breast cancer will come back. The higher the score is, the greater the chances that the breast cancer will come back. Hope S. Rugo, MD, of UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses how the Recurrence…
Dr Susan K. Boolbol talks about the importance of objective evidence provided by the Breast Cancer Index (BCI) in treatment decision making. For more information, visit: http://www.breastcancerindex.com http://www.answersbeyond5.com http://www.twitter.com/answersbyond5 http://www.facebook.com/answersbeyond5
Dr. Boccia describes cases in which he uses CancerTYPE ID in his clinical practice. For more information, visit: http://www.cancertypeid.com
At the 9th European Breast Cancer Conference (EBCC), Matti Aapro, MD, of Clinique de Genolier, Genolier, Switzerland, and Daniel Rea, MBBS, BSc, PhD, FRCP, of the University of Birmingham, Birmingham, United Kingdom, UK, discuss the molecular diversity of breast cancer. They explain that patients with breast cancer can be categorised using molecular tools to help guide clinical decision-making. Focusing on giving clinicians practical advice for the consultation room, they review the results of the Multidisciplinary Application of Genomics in Clinical Practice (MAGIC) survey, which evaluated patient attributes and clinician attitudes considered for decision-making with regard to adjuvant chemotherapy in early…
Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute, UK, disusses the results of the CheckMate 067 trial, a phase 3 trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma. NIVO combined with IPI and NIVO alone had superior clinical activity versus IPI alone. The results with NIVO combined with IPI and NIVO alone further suggest complementary activity of the two agents. There were no new safety signals or drug-related deaths observed with the combination. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Eleni Efstathiou, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results of a study that evaluated the clinical and biological heterogeneity of response and resistance to neoadjuvant abiraterone acetate, a prodrug of abiraterone, a CYP17 inhibitor that lowers serum testosterone, plus leuprolide acetate, a luteinizing hormone-releasing hormone agonist (LHRHa), versus LHRHa in patients with localised high-risk prostate cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Hope S. Rugo, MD, of UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, explains the Oncotype DX® Breast Cancer Assay and how it is performed, detailing the specificities of the test and how the Recurrence Score® result is reported. She highlights how her multidisciplinary team chooses to use a genomic test, such as the Oncotype DX assay, to guide adjuvant chemotherapy decisions in luminal breast cancers. She comments on the use of the Oncotype DX assay with traditional markers and other markers such as ER, PR or HER2. The Recurrence Score result is complementary for select patients. Her…
Anne Armstrong, MRCP, PhD, MB ChB, BSc(Hons), of The Christie Hospital, Manchester, UK, and Nigel Bundred, MD, FRCS, of The University of Manchester, UK, discuss genomic profiling for patients with breast cancer and the Oncotype DX® Breast Cancer Assay. This content is supported by Genomic Health, Inc. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Hope S. Rugo, MD, of UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, shares her experience on the recommended treatment approach for oestrogen receptor (ER)-positive, HER2-negative breast cancer patients. Prof Rugo comments on the expected benefit of adjuvant chemotherapy and endocrine therapy in luminal breast cancers and mentions that one of the greatest challenges is to understand the heterogeneity of the tumour. She also comments on the use of criteria, such as tumour grade and size, to select patients for adjuvant chemotherapy as well as the usage of immunohistochemistry (IHC) markers, such as hormone receptor markers, to identify…